668 related articles for article (PubMed ID: 32365199)
1. Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.
Islam MS; Afrin S; Jones SI; Segars J
Endocr Rev; 2020 Oct; 41(5):. PubMed ID: 32365199
[TBL] [Abstract][Full Text] [Related]
2. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety.
Bouchard P; Chabbert-Buffet N; Fauser BC
Fertil Steril; 2011 Nov; 96(5):1175-89. PubMed ID: 21944187
[TBL] [Abstract][Full Text] [Related]
3. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
4. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
5. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.
Chwalisz K; Perez MC; Demanno D; Winkel C; Schubert G; Elger W
Endocr Rev; 2005 May; 26(3):423-38. PubMed ID: 15857972
[TBL] [Abstract][Full Text] [Related]
6. [Selective progesterone receptor modulators and their therapeutical use].
Driák D; Sehnal B; Svandová I
Ceska Gynekol; 2013 Apr; 78(2):175-81. PubMed ID: 23710982
[TBL] [Abstract][Full Text] [Related]
7. Vilaprisan for treating uterine fibroids.
Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
[TBL] [Abstract][Full Text] [Related]
8. Selective progesterone receptor modulators: current applications and perspectives.
Chabbert-Buffet N; Kolanska K; Daraï E; Bouchard P
Climacteric; 2018 Aug; 21(4):375-379. PubMed ID: 29338440
[TBL] [Abstract][Full Text] [Related]
9. Selective progesterone receptor modulators.
Whitaker LH; Williams AR; Critchley HO
Curr Opin Obstet Gynecol; 2014 Aug; 26(4):237-42. PubMed ID: 24950125
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
11. Selective progesterone receptor modulators: an update.
Benagiano G; Bastianelli C; Farris M; Brosens I
Expert Opin Pharmacother; 2014 Jul; 15(10):1403-15. PubMed ID: 24787486
[TBL] [Abstract][Full Text] [Related]
12. The state-of-the-art of emergency contraception with the cutting edge drug.
Sarkar NN
Ger Med Sci; 2011; 9():Doc16. PubMed ID: 21808601
[TBL] [Abstract][Full Text] [Related]
13. Next step in the development of mesoprogestins: the preclinical profile of EC313.
Błaszczak-Świątkiewicz K; Krupa A; Mnich E; Elger W; Oettel M; Nair H; Wierzbicki M; Sieroszewski P; Shaked Z
Front Endocrinol (Lausanne); 2023; 14():1201547. PubMed ID: 37766684
[TBL] [Abstract][Full Text] [Related]
14. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids.
Bestel E; Donnez J
Expert Rev Endocrinol Metab; 2014 Jan; 9(1):79-92. PubMed ID: 30743741
[TBL] [Abstract][Full Text] [Related]
15. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
16. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies.
Möller C; Bone W; Cleve A; Klar U; Rotgeri A; Rottmann A; Schultze-Mosgau MH; Wagenfeld A; Schwede W
ChemMedChem; 2018 Nov; 13(21):2271-2280. PubMed ID: 30407750
[TBL] [Abstract][Full Text] [Related]
18. Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs).
Schubert G; Elger W; Kaufmann G; Schneider B; Reddersen G; Chwalisz K
Semin Reprod Med; 2005 Feb; 23(1):58-73. PubMed ID: 15714390
[TBL] [Abstract][Full Text] [Related]
19. Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development.
Nelson AL
Expert Opin Investig Drugs; 2015; 24(10):1321-30. PubMed ID: 26289789
[TBL] [Abstract][Full Text] [Related]
20. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies.
Wagenfeld A; Saunders PT; Whitaker L; Critchley HO
Expert Opin Ther Targets; 2016 Sep; 20(9):1045-54. PubMed ID: 27138351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
